PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

DOACs Versus Warfarin for VTE in Sickle Cell Disease: Bayesian Pooling

direct oral anticoagulantsDOACsvitamin K antagonistswarfarinapixabanrivaroxabanedoxabandabigatransickle cell diseasevenous thromboembolismmajor bleedingBayesian meta-analysisobservational studiesanticoagulation Anticoagulation / Hematology

Background Information

DOACs could offer safer VTE management in sickle cell patients.

Choosing the right anticoagulant for venous thromboembolism (VTE) in sickle cell disease (SCD) is crucial for safety and efficacy. Direct oral anticoagulants (DOACs) reduce major bleeding (OR 0.25; 95% CrI, 0.07-0.80) but show similar efficacy to vitamin K antagonists (VKAs) for VTE. DOACs may offer a safer alternative to VKAs in SCD patients with VTE, but results are from retrospective studies, needing further research. In SCD with VTE, DOACs may lower major bleeding risks compared to VKAs.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Le Jeune S, Mahé I, Morabito A, Datchanamourty J, Happe F, Versini E, Affo L, Frere C

Citation: Le Jeune S, Mahé I, Morabito A, et al. Direct oral anticoagulants versus vitamin K antagonists for the treatment of venous thromboembolism in adults with sickle cell disease: a Bayesian meta-analysis. Research and practice in thrombosis and haemostasis. 2026;10(7):107015. doi:10.1016/j.rpth.2026.107015

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.